Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter studyEva Ellebæk, Dirk Schadendorf, Patrick Terheyden et al.|EJC Skin Cancer|2025Cited by 1
Erratum to “Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study” [EJC Skin Cancer 4 (2026) 100773]Eva Ellebaek, Dirk Schadendorf, Michael Weichenthal et al.|EJC Skin Cancer|2026Cited by 0